CTMX CYTOMX THERAPEUTICS INC Management Changes 8-K Filing 2025 - Management Change CytomX Therapeutics announced the termination of Jeffrey Landau, Chief Business Officer, effective February 7, 2025, with a Separation Agreement providing economic payments and a general release of claims.Get access to all SEC 8-K filings of the CYTOMX THERAPEUTICS INC